Erasmus MC Cancer Institute
Rotterdam's OECI-accredited comprehensive cancer centre, where peptide receptor radionuclide therapy with lutetium-177 was pioneered and Europe's largest screening trials were led.
Overview
Erasmus MC Cancer Institute unites the former Daniel den Hoed cancer clinic with the oncology departments of Erasmus University Medical Center and holds OECI comprehensive cancer centre accreditation. Its nuclear medicine group under Eric Krenning and Dik Kwekkeboom developed somatostatin-receptor imaging and then 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendocrine tumours, the treatment later validated in NETTER-1 and approved as Lutathera. Erasmus MC epidemiologists coordinated the European Randomized Study of Screening for Prostate Cancer and the NELSON lung screening trial, which showed a mortality reduction from low-dose CT screening. The institute co-founded the Holland Proton Therapy Centre in Delft with LUMC and TU Delft, and is a leading sarcoma, breast and neuro-oncology trial site under Stefan Sleijfer.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to Erasmus MC Cancer Institute, including child institutions. 876 works · 11,159 citations · 91% open access · 14% clinical trials · 3% reviews.
- Bas Groot Koerkamp176 works
- Marc G. Besselink169 works
- Dirk Jan Grünhagen107 works
- Cornelis Kees Verhoef94 works
- Izaak Quintus Molenaar93 works
- Ignace H. J. T. de Hingh84 works
- Casper H.J. van Eijck83 works
- Olivier R. Busch80 works
- Hjalmar C. van Santvoort77 works
- Johanna W. Wilmink74 works
- Peptide receptor radionuclide therapy
- Cancer screening trials (ERSPC, NELSON)
- Holland Proton Therapy Centre
- Sarcoma
- Neuro-oncology
Similar pages
not linked directly; found by shared links- InstitutionUppsala University Hospital / Uppsala University
Shares Glioma & glioblastoma, Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours.
- InstitutionInselspital, Bern University Hospital / University Cancer Center Inselspital
Shares Glioma & glioblastoma, Theranostics, Somatostatin receptor 2, Lutetium-177 dotatate.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Theranostics, Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours.
- PersonSimron Singh
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonEmily K. Bergsland
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- Key paperNETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours
Shares Theranostics, Novartis, Somatostatin receptor 2, Lutetium-177 dotatate.
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- IndicationHereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)
Shares CT (computed tomography), Somatostatin receptor 2, Lutetium-177 dotatate, Radioligand therapy (beta emitters).